Colorectal cancer is the third most common cancer in the world with increasing incidence
and mortality rates globally. Standard treatments for colorectal cancer have always been …

The number of molecularly stratified treatment options available to patients with colorectal
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …

Colorectal cancer (CRC) is the third most common cancer worldwide, with 1.1 million new
cases per year, and is the second leading cause of cancer death. 1 CRC occurs more …

Deep learning (DL) can accelerate the prediction of prognostic biomarkers from routine
pathology slides in colorectal cancer (CRC). However, current approaches rely on …

Recent studies have highlighted the biological significance of RNA N 6-methyladenosine (m
6 A) modification in tumorigenicity and progression. However, it remains unclear whether m …

Colorectal cancer (CRC) is one of the most common malignancies in Western countries.
Over the last 20 years, and the last decade in particular, the clinical outcome for patients with …

Japanese mortality due to colorectal cancer is on the rise, surpassing 49,000 in 2015. Many
new treatment methods have been developed during recent decades. The Japanese …

Background The triplet FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus
bevacizumab showed improved outcomes for patients with metastatic colorectal cancer …

Systemic inflammation is a marker of poor prognosis preoperatively present in around 20%-
40% of colorectal cancer patients. The hallmarks of systemic inflammation include an …

In 2012, there were 447000 new cases of colorectal cancer (CRC) in Europe. CRC is the
second most frequent cancer and represents 13.2% and 12.7% of all cancer cases in men …